| abstract |
Curable formulation comprising: (i) a curable benzoxazine macromonomer; and (ii) a curable component other than the curable benzoxazine macromonomer selected from the group of N-aliphatic dibenzoxazines and N-aliphatic monobenzoxazines; wherein the curable benzoxazine macromonomer (i) contains at least 3 benzoxazine rings and at least one aliphatic, heteroaliphatic, araliphatic, heteroaraliphatic, aromatic or heteroaromatic moiety, the moiety comprising the shortest chain of atoms containing at least 40 atoms between two benzoxazine nitrogen atoms or between two benzoxazine oxygen atoms, and said chain of atoms must not include any oxazine ring atoms ("soft fragment"). |